Organ and prenatal toxicity of nonsteroidal anti-inflammatory drugs

1. Alano M.A. et al.: Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics, 107, 519-523, 2001.10.1542/peds.107.3.519Search in Google Scholar

2. Beck S.L.: Prenatal and postnatal assessment of maneb-exposed CD-1 mice. Reprod. Toxicol., 4, 83-290, 1990.10.1016/0890-6238(90)90040-3Search in Google Scholar

3. Bombardier C. et al.: VIGOR Study Group.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med., 343, 1520-1528, 2000.Search in Google Scholar

4. Briggs GG. et al.: Drugs in pregnancy and lactation. A reference guide to fetal and neonatal risk. Lippincott Williams & Wilkins, Philadelphia, 2005.Search in Google Scholar

5. Burdan F. et al.: Celosomy is associated with prenatal exposure to cyclo-oxygenase inhibitors. Pharmacol. Res., 53, 287-292, 2006.10.1016/j.phrs.2005.12.006Search in Google Scholar

6. Burdan F. et al.: Congenital ventricular septal defects and prenatal exposure to cyclooxygenase inhibitors. Braz. J. Med. Biol. Res., 39, 925-934, 2006.10.1590/S0100-879X2006000700011Search in Google Scholar

7. Burdan F. et al.: Immuno-expression of the constitutive and inducible cyclo-oxygenase isoforms in maternal and fetal rat lungs. Ann. Univ. Mariae Curie Sklodowska Med. [Sectio D], 61, 330-334, 2006.Search in Google Scholar

8. Burdan F. et al.: Localization of cyclo-oxygenase isoforms in maternal and offspring kidney during pregnancy and lactation. Ann. Univ. Mariae Curie Sklodowska Med. [Sectio D], 61, 326-329, 2006.Search in Google Scholar

9. Burdan F. et al.: Prenatal effects of DuP-697 - the irreversible, highly selective cyclo-oxygenase-2 inhibitor. Reprod. Toxicol., 17, 413-419, 2003.10.1016/S0890-6238(03)00045-5Search in Google Scholar

10. Burdan F. et al.: Skeletal developmental effects of selective and nonselective cyclo-oxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL.(WI)WUBR rats. Toxicology, 216, 204-223, 2005.10.1016/j.tox.2005.08.009Search in Google Scholar

11. Burdan F. et al.: Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclo-oxygenase inhibitors. Pharmacol. Res., 64, 521-527, 2012.10.1016/S1734-1140(12)70847-2Search in Google Scholar

12. Burdan F.: Comparison of developmental toxicity of selective and non-selective cyclo-oxygenase-2 inhibitors in CRL.(WI)WUBR Wistar rats - DFU and piroxicam study. Toxicology, 211, 12-25, 2005.10.1016/j.tox.2005.02.00515863244Search in Google Scholar

13. Burdan F.: Developmental effects of propyphenazone in analgesic and antipyretic combination with caffeine or paracetamol. Hum. Exp. Toxicol., 23, 235-244, 2004.10.1191/0960327104ht439oa15222401Search in Google Scholar

14. Burdan F.: Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL.(WI) WUBR rats. Birth Defects Res Part B Dev Reprod. Toxicol., 71, 321-330, 2004.10.1002/bdrb.2001815505808Search in Google Scholar

15. Burdan F.: Intrauterine growth retardation and lack of teratogenic effects of prenatal exposure to the combination of paracetamol and caffeine in Wistar rats. Reprod. Toxicol., 17, 51-58, 2003.10.1016/S0890-6238(02)00097-7Search in Google Scholar

16. Cannon C.P. et al.: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis, in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet, 368, 1771-1781, 2006.10.1016/S0140-6736(06)69666-9Search in Google Scholar

17. Carter A.M.: Evolution of factors affecting placental oxygen transfer. Placenta, 2009, 19-25.10.1016/j.placenta.2008.11.00619070361Search in Google Scholar

18. Chaiamnuay S. et al.: Risks versus benefits of cyclo-oxygenase-2- selective nonsteroidal anti-inflammatory drugs. Am. J. of Health- System Pharm., 19, 1848-1851, 2006.10.2146/ajhp05051916990630Search in Google Scholar

19. Chernoff N. et al.: Significance of supernumerary ribs in rodent developmental toxicity studies: postnatal persistence in rats and mice. Fundam. Appl. Toxicol., 17, 448-453, 1991.10.1093/toxsci/17.3.448Search in Google Scholar

20. Cook J.C. et. al.: Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth. Defects Res. B. Dev. Reprod. Toxicol., 68, 5-26, 2003.10.1002/bdrb.1000512852480Search in Google Scholar

21. Dingle J.T. The effects of NSAID on the matrix human articular cartilages. Z. Rheumatol., 58, 125-129, 1999.10.1007/s00393005016110441838Search in Google Scholar

22. Fritz H.: Prenatal ossification in rabbits as indicative of fetal maturity. Teratology. 11. 313-319, 1975.10.1002/tera.14201103101154293Search in Google Scholar

23. Hippisley-Cox J., Coupland C.: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested casecontrol analysis. Br. Med. J., 330, 1366, 2005.Search in Google Scholar

24. Khan K.N. et al.: Expression of cyclo-oxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure and nephropathy. Ren Fail., 23, 321-330, 2001.10.1081/JDI-10010471611499548Search in Google Scholar

25. Khera K.S.: Common fetal aberrations and their teratologic significance: a review. Fundam. Appl. Toxicol., 1, 13-18, 1981.10.1093/toxsci/1.1.136135638Search in Google Scholar

26. Mandell B.F.: General tolerability and use of nonsteroidal antiinfammatory drugs. Am. J. Med., 107, 72-76, 1999.10.1016/S0002-9343(99)00370-8Search in Google Scholar

27. Mardini I.A. Fitzgerald G.A.: Selective inhibitors of cyclooxygenase-2. Am. Soci. Pharm. Exp. Therap., 1, 30-43, 2001.Search in Google Scholar

28. Markowitz G.S. et al.: Membranous glomerulopathy and acute interstitial nephritis fallowing treatment with celecoxib. Clin. Nephrol., 59, 137-142, 2003.10.5414/CNP59137Search in Google Scholar

29. Radi Z.A., Khan N.K.: Effects of cyclo-oxygenase inhibition on the gastrointestinal tract. Exp. Toxicol. Pathol., 58, 163-173, 2006.10.1016/j.etp.2006.06.004Search in Google Scholar

30. Østensen M., et al. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology (Oxford)., 50, 657-664, 2011.Search in Google Scholar

31. alhab A.S. et al.: Meloxicam inhibits rabbit ovulation. Contraception. 63, 329-333, 2001.10.1016/S0010-7824(01)00207-4Search in Google Scholar

32. Sanchez-Borges M.: Tolerability to new COX-2 inhibitors in NSAIDsensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol., 87, 201-204, 2001.10.1016/S1081-1206(10)62226-0Search in Google Scholar

33. angha R.K. et al.: Immunohistochemical localization, messenger ribonucleic acid abundance, and activity of 15-hydroxyprostaglandin dehydrogenase in placenta and fetal membranes during term and preterm labor. J. Clin. Endocrinol. Metab., 78, 982-989, 1994.10.1210/jc.78.4.982Search in Google Scholar

34. Scheaffer C. et al.: Drugs during pregnancy and lactation. 2 ed. (2007). Academic Press; Londyn.Search in Google Scholar

35. Scialli A.R. et al.: Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res. A. Clin. Mol. Teratol., 70, 7-12, 2004.10.1002/bdra.10150Search in Google Scholar

36. Sibal B.M., et al.: Low-dose aspirin in pregnancy. Obstet. Gynecol., 74, 551-557, 1989.Search in Google Scholar

37. Silverstein F.E. et all.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 284, 1247-1255, 2000.10.1001/jama.284.10.1247Search in Google Scholar

38. Szczeklik A. et al.: Safety of a specific COX-2 inhibitor in aspirin induced asthma. Clin. Exp. Allergy., 31, 219-225, 2001.10.1046/j.1365-2222.2001.01075.xSearch in Google Scholar

39. Torfs C.P. et al.: Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology, 54, 84-92, 1996.10.1002/(SICI)1096-9926(199606)54:2<84::AID-TERA4>3.0.CO;2-4Search in Google Scholar

40. Vermillion S.T. et al.: The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am. J. Obstet. Gynecol., 177, 256-261, 1997.10.1016/S0002-9378(97)70184-4Search in Google Scholar

41. Werler M.M., et al.: Use of over-the-counter medications during pregnancy. Am. J. Obstet. Gynecol., 193, 771-777, 2005.10.1016/j.ajog.2005.02.100Search in Google Scholar

42. Yasuda S. et al.: Placental folate transport during pregnancy. Biosci. Biotechnol. Biochem., 72, 2277-2284, 2008.10.1271/bbb.80112Search in Google Scholar

43. Zimmerman H.J. Ishak K.G. General aspects of drug induced liver disease. Gastroenterol. Clin. North Am., 24, 793-757, 1995. 10.1016/S0889-8553(21)00226-0Search in Google Scholar